Clinical Study

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating The Use Of Adjuvant Endocrine Therapy +/- One Year Of Everolimus In Patients With High-Risk, Hormone Receptor-Positive And Her2/Neu Negative Breast Cancer

Posted Date: Jul 15, 2017

  • Investigator: John Morris
  • Specialties: Hematology/Oncology, Oncology
  • Type of Study: Drug

This study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without patients cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. Everolimus is currently approved for the treatment of advanced or metastatic kidney cancer, it is considered investigational for breast cancer patients. Patients will get hormone treatment with either everolimus or with placebo.


Eligible Patients Must Have Hormone Responsive Breast Cancer That Has Already Been Removed By Surgery And Have Completed Any Required Chemotherapy Or Radiation


Brca, Breast Cancer, Her2, Metastatic Breast Cancer, S1207

For More Information:

Uc Cancer Institute